Topical tretinoin prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect.
Kligman
L H
LH
Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia.
Schwartz
E
E
Lesnik
R H
RH
Mezick
J A
JA
D000279:Administration, Cutaneous; D000818:Animals; D001284:Atrophy / Q000517:prevention & control; D003436:Croton Oil / Q000633:toxicity; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology; D004431:Ear, External; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D005353:Fibronectins / Q000032:analysis; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D006025:Glycosaminoglycans / Q000032:analysis; D007249:Inflammation; D051379:Mice; D008812:Mice, Hairless; D012867:Skin / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity; D014212:Tretinoin / Q000008:administration & dosage / Q000494:pharmacology*
D005353:Fibronectins; D005938:Glucocorticoids; D006025:Glycosaminoglycans; D014212:Tretinoin; D003436:Croton Oil; D013755:Tetradecanoylphorbol Acetate